Department of Neuropathology, Institute of Pathology, Ruprecht-Karls-University Heidelberg, INF 224, 69120, Heidelberg, Germany.
Acta Neuropathol. 2013 May;125(5):651-8. doi: 10.1007/s00401-013-1117-6. Epub 2013 Apr 11.
Non-central nervous system hemangiopericytoma (HPC) and solitary fibrous tumor (SFT) are considered by pathologists as two variants of a single tumor entity now subsumed under the entity SFT. Recent detection of frequent NAB2-STAT6 fusions in both, HPC and SFT, provided additional support for this view. On the other hand, current neuropathological practice still distinguishes between HPC and SFT. The present study set out to identify genes involved in the formation of meningeal HPC. We performed exome sequencing and detected the NAB2-STAT6 fusion in DNA of 8/10 meningeal HPC thereby providing evidence of close relationship of these tumors with peripheral SFT. Due to the considerable effort required for exome sequencing, we sought to explore surrogate markers for the NAB2-STAT6 fusion protein. We adopted the Duolink proximity ligation assay and demonstrated the presence of NAB2-STAT6 fusion protein in 17/17 HPC and the absence in 15/15 meningiomas. More practical, presence of the NAB2-STAT6 fusion protein resulted in a strong nuclear signal in STAT6 immunohistochemistry. The nuclear reallocation of STAT6 was detected in 35/37 meningeal HPC and 25/25 meningeal SFT but not in 87 meningiomas representing the most important differential diagnosis. Tissues not harboring the NAB2-STAT6 fusion protein presented with nuclear expression of NAB2 and cytoplasmic expression of STAT6 proteins. In conclusion, we provide strong evidence for meningeal HPC and SFT to constitute variants of a single entity which is defined by NAB2-STAT6 fusion. In addition, we demonstrate that this fusion can be rapidly detected by STAT6 immunohistochemistry which shows a consistent nuclear reallocation. This immunohistochemical assay may prove valuable for the differentiation of HPC and SFT from other mesenchymal neoplasms.
非中枢神经系统血管外皮细胞瘤(HPC)和孤立性纤维瘤(SFT)被病理学家视为单一肿瘤实体的两种变体,现在归入 SFT 实体。最近在 HPC 和 SFT 中均频繁检测到 NAB2-STAT6 融合,为这种观点提供了更多支持。另一方面,目前的神经病理学实践仍然区分 HPC 和 SFT。本研究旨在确定脑膜 HPC 形成中涉及的基因。我们进行了外显子组测序,并在 10 例脑膜 HPC 的 DNA 中检测到 NAB2-STAT6 融合,从而提供了这些肿瘤与外周 SFT 密切相关的证据。由于外显子组测序需要大量的努力,我们试图探索 NAB2-STAT6 融合蛋白的替代标志物。我们采用 Duolink 邻近连接测定法,在 17/17 例 HPC 中证实了 NAB2-STAT6 融合蛋白的存在,而在 15/15 例脑膜瘤中则不存在。更实用的是,NAB2-STAT6 融合蛋白的存在导致 STAT6 免疫组化中的核信号强烈。在 37 例脑膜 HPC 和 25 例脑膜 SFT 中检测到 STAT6 的核重排,但在代表最重要鉴别诊断的 87 例脑膜瘤中则没有。不携带 NAB2-STAT6 融合蛋白的组织表现为 NAB2 的核表达和 STAT6 蛋白的细胞质表达。总之,我们为脑膜 HPC 和 SFT 提供了强有力的证据,表明它们是由 NAB2-STAT6 融合定义的单一实体的变体。此外,我们证明该融合可以通过 STAT6 免疫组化快速检测,该检测显示出一致的核重排。这种免疫组织化学检测可能对鉴别 HPC 和 SFT 与其他间质性肿瘤具有重要价值。